



***Flowflex*<sup>TM</sup> SARS-CoV-2 Antigen Rapid Test  
Evaluation Report**

**November 2020**

## Flowflex SARS-CoV-2 Antigen Rapid Test Evaluation Report

The Flowflex SARS-CoV-2 Antigen Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasal and nasopharyngeal swab specimens directly from individuals who are suspected of COVID-19 by their healthcare provider within the first seven days of the onset of symptoms. The Flowflex SARS-CoV-2 Antigen Rapid Test does not differentiate between SARS-CoV and SARS-CoV-2.

Results are for the identification of SARS-CoV-2 nucleocapsid antigen. This antigen is generally detectable in upper respiratory samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.

Negative results from patients with more than seven days post symptom onset should be treated as presumptive and confirmed with a molecular assay, if necessary, for patient management. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.

The Flowflex SARS-CoV-2 Antigen Rapid Test is intended for use by trained clinical laboratory personnel and individuals trained in point of care settings.

1. **Purpose:** To evaluate the performance of the Flowflex SARS-CoV-2 Antigen Rapid Test

2. **Study procedure and results**

### 2.1 Imprecision/reproducibility Study

#### Material:

- SARS-CoV-2 Antigen Rapid Test, Lot#1:202009101, Lot#2:202009001, Lot#3:202009201
- Extraction Buffer, Lot1#:202008001, Lot2#:202008002, Lot3#:202008003
- SARS-CoV-2 Antigen Negative Sample Lot#: COVAG200904N
- SARS-CoV-2 Antigen Low Positive Sample P3 Lot#: COVAG200904P3
- SARS-CoV-2 Antigen Middle Positive Sample P2 Lot#: COVAG200904P2
- SARS-CoV-2 Antigen High Positive Sample P1 Lot#: COVAG200904P1

#### Procedure:

3 Lots of SARS-CoV-2 Antigen Rapid Test were tested according to the package insert by 3 operators. Each operator performed 2 tests on each control for 5 days in 2 sites in China. Total 180 tests were performed per each control: 2 replicates X 5 days X 3 lots X 3 operators X 2 sites = 180 tests.

**Test results:**

SARS-CoV-2 Samples	Lot 1	Lot 2	Lot 3
High Pos	+ / 60 replicates	+ / 60 replicates	+ / 60 replicates
Mid Pos	+ / 60 replicates	+ / 60 replicates	+ / 60 replicates
Low Pos	+ / 60 replicates	+ / 60 replicates	+ / 60 replicates
Neg	- / 60 replicates	- / 60 replicates	- / 60 replicates

**Conclusions:**

All three lots identified the samples 100% correctly as negative or positive.

**2.2 Limit of Detection (LOD)**

**Material:**

- SARS-CoV-2 Antigen Rapid Test, Lot#1:202009101, Lot#2:202009001, Lot#3:202009201
- Extraction Buffer, Lot1#:202008001, Lot2#:202008002, Lot3#:202008003
- SARS-CoV-2 viral culture

**Procedure:**

Procedure 1:

- 1) Diluted the high concentration SARS-CoV-2 virus culture with the negative nasal matrix sample pool to  $2.56 \times 10^3$  TCID<sub>50</sub>/mL. And then diluted the  $2.56 \times 10^3$  TCID<sub>50</sub>/mL sample with negative nasal matrix sample pool with 2-fold serial dilutions.
- 2) Used 3 lots of SARS-CoV-2 antigen rapid test to test the samples, and each sample was tested in 10 replicates. And calculated the detectable rate for each sample.
- 3) The minimum concentration with  $\geq 95\%$  detectable rate was defined as the minimum detectability (LoD) for nasal swab specimens.

Procedure 2:

- 1) Diluted the high concentration SARS-CoV-2 virus culture with the negative nasopharyngeal matrix sample pool to  $2.56 \times 10^3$  TCID<sub>50</sub>/mL. And then diluted the  $2.56 \times 10^3$  TCID<sub>50</sub>/mL sample with negative nasopharyngeal matrix sample pool with 2-fold serial dilutions.
- 2) Used 3 lots of SARS-CoV-2 antigen rapid test to test the samples, and each sample was tested in 10 replicates. And calculated the detectable rate for each sample.
- 3) The minimum concentration with  $\geq 95\%$  detectable rate was defined as the minimum detectability (LoD) for nasopharyngeal swab specimens.

**Test results:**

**For nasal swab specimens:**

Concentration	Lot	Test Result	Detectable rate
$2.56 \times 10^3$ TCID <sub>50</sub> /mL	Lot 1	+ / 10 replicates	100% (30/30)
	Lot 2	+ / 10 replicates	

	<b>Lot 3</b>	+ / 10 replicates	
1.28 x 10 <sup>3</sup> TCID <sub>50</sub> /mL	<b>Lot 1</b>	+ / 10 replicates	100% (30/30)
	<b>Lot 2</b>	+ / 10 replicates	
	<b>Lot 3</b>	+ / 10 replicates	
6.4 x 10 <sup>2</sup> TCID <sub>50</sub> /mL	<b>Lot 1</b>	+ / 10 replicates	100% (30/30)
	<b>Lot 2</b>	+ / 10 replicates	
	<b>Lot 3</b>	+ / 10 replicates	
3.2 x 10 <sup>2</sup> TCID <sub>50</sub> /mL	<b>Lot 1</b>	+ / 10 replicates	100% (30/30)
	<b>Lot 2</b>	+ / 10 replicates	
	<b>Lot 3</b>	+ / 10 replicates	
1.6 x 10 <sup>2</sup> TCID <sub>50</sub> /mL	<b>Lot 1</b>	+ / 10 replicates	96.7% (29/30)
	<b>Lot 2</b>	+ / 10 replicates	
	<b>Lot 3</b>	+ 9 replicates / - 1 replicate	
8 x 10 TCID <sub>50</sub> /mL	<b>Lot 1</b>	- / 10 replicates	0% (0/30)
	<b>Lot 2</b>	- / 10 replicates	
	<b>Lot 3</b>	- / 10 replicates	

**For nasopharyngeal swab specimens:**

Concentration	Lot	Test Result	Detectable rate
2.56 x 10 <sup>3</sup> TCID <sub>50</sub> /mL	<b>Lot 1</b>	+ / 10 replicates	100% (30/30)
	<b>Lot 2</b>	+ / 10 replicates	
	<b>Lot 3</b>	+ / 10 replicates	
1.28 x 10 <sup>3</sup> TCID <sub>50</sub> /mL	<b>Lot 1</b>	+ / 10 replicates	100% (30/30)
	<b>Lot 2</b>	+ / 10 replicates	
	<b>Lot 3</b>	+ / 10 replicates	

6.4 x 10 <sup>2</sup> TCID <sub>50</sub> /mL	Lot 1	+ / 10 replicates	100% (30/30)
	Lot 2	+ / 10 replicates	
	Lot 3	+ / 10 replicates	
3.2 x 10 <sup>2</sup> TCID <sub>50</sub> /mL	Lot 1	+ / 10 replicates	100% (30/30)
	Lot 2	+ / 10 replicates	
	Lot 3	+ / 10 replicates	
1.6 x 10 <sup>2</sup> TCID <sub>50</sub> /mL	Lot 1	+ / 10 replicates	100% (30/30)
	Lot 2	+ / 10 replicates	
	Lot 3	+ / 10 replicates	
8 x 10 TCID <sub>50</sub> /mL	Lot 1	- / 10 replicates	0% (0/30)
	Lot 2	- / 10 replicates	
	Lot 3	- / 10 replicates	

**Conclusion:**

According to the test result, the LOD of SARS-CoV-2 Antigen Rapid Test is 1.6 x 10<sup>2</sup> TCID<sub>50</sub>/mL for nasal and nasopharyngeal swab specimens.

**2.3 Clinical study**

A multi-site clinical study was conducted to evaluate the performance of the SARS-CoV-2 Antigen Rapid Test, and the results are shown below.

**2.3.1 Study in China – nasal swabs**

**Clinical site:**

Sample collection and testing site	Responsible person/Qualification	Coordinator/Qualification
Shenzhen CDC No. 8 Longyuan Road, Nanshan District, Shenzhen, P.R. China	Renli Zhang, MD	Fangli Tong, Technologist
Adicon No.208 Zhenzhong Road, West Lake District, Hangzhou, Zhejiang, P.R. China	Cheng Zeng, Technologist	

**Material:**

- SARS-CoV-2 Antigen Rapid Test, Lot# 202009001
- Jiangsu Changfeng Medical nasal swabs
- Comparison method: RT-PCR, Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (PCR-Fluorescence Probing), manufactured by Sansure BioTech Inc.
- Extraction Buffer, Lot1#:202008001
- Nasal swab samples from infected patients and non-infected patients

**Procedure:**

1. Study was conducted in China
  - 452 clinical nasal swabs were collected from patients who were suspected of COVID-19. All the samples were confirmed with RT-PCR.
  - 70 positive clinical nasal swabs collected from patients. 63 samples with Ct counts <33, 7 samples with Ct counts  $\geq$ 33.
2. Following product package insert, performed the test and read the result at reading time.

**Test results:**

Candidate method		RT-PCR method		
		Negative	Positive	Total
Flowflex Test Results	Negative	381	2*	383
	Positive	1	68	69
	Total	382	70	452

\*2 samples with PCR CT value 34-35

**2.3.2 Clinical Study in USA – nasal swabs**

**Clinical sites:**

- Sample collection sites in USA:

Patient sample collection site	Responsible person/Qualification	Coordinator/Qualification
Boca Raton 6877 SW 18th Street Boca Raton, FL 33433	Dr. Peter Miller, MD	David Cantor, CRO
COVID CLINIC Westminster (WM) 2109 Westminster Mall Westminster, CA 92683	Dr. Matthew Abinante, DO, MPH	
COVID CLINIC La Mesa (LM) 5601 Grossmont Center Drive La Mesa, CA 91942		

COVID CLINIC Downtown San Diego 1350 Third Avenue San Diego, CA 92101		
--	--	--

- Testing sites in USA:

Testing sites	Operator name/Qualification	Coordinator /Qualification
7200 Parkway Drive, Suite 117 La Mesa, CA 91942	Dr. Shannyn Fowl, MD	David Cantor, CRO
COVID CLINIC Westminster (WM) 2109 Westminster Mall Westminster, CA 92683	Dr. Matthew Abinante, DO, MPH	
COVID CLINIC La Mesa (LM) 5601 Grossmont Center Drive La Mesa, CA 91942		
COVID CLINIC Downtown San Diego 1350 Third Avenue San Diego, CA 92101		

**Material:**

- SARS-CoV-2 Antigen Rapid Test, Lot# 202009001
- Puritan Medical Products nasal swabs (#25-1506 1PF 100), and Jiangsu Changfeng Medical nasal swabs
- Comparison method:  
TaqPath COVID-19 Combo Kit, FDA authorized RT-PCR test for emergency use, manufactured by Thermo Fisher Scientific, Inc.  
CDC 2019-nCoV RT-PCR, ABI 7500DX, FDA authorized RT-PCR test for emergency use
- Nasal swab samples from infected patients and non-infected patients

**Procedure:**

1. Study is being conducted in multiple U.S. sites in California and Florida, and it is ongoing. So far, 153 clinical nasal swabs were collected from patients who were suspected of COVID-19. All the samples were confirmed with RT-PCR method.
2. Following product package insert, performed the test and read the result at reading time.

**Test results:**

Candidate method		RT-PCR method		
		Negative	Positive	Total
Flowflex Test Results	Negative	52	3*	55
	Positive	1	97	98
	Total	53	100	153

\*3 samples with PCR CT value 32.9-33

**2.3.3 Summary of combined clinical studies at all sites– nasal swabs:**

Candidate method		RT-PCR method		
		Negative	Positive	Total
Flowflex Test Results	Negative	433	5	438
	Positive	2	165	167
	Total	435	170	605

	Performance	95% CI
Sensitivity	97.1% (165/170)	93.1%-98.9%
Specificity	99.5% (433/435)	98.2%- 99.9%
Accuracy	98.8% (598/605)	97.6% -99.5%

**2.3.4 Additional Clinical Study in USA – nasopharyngeal swabs**

A total of 37 samples consisting of 7 positive nasopharyngeal (NP) swabs and 30 negative NP swab specimens were tested. NP swab specimens collected from the patients with COVID-19 like symptoms in the U.S during the 2020 COVID-19 season were provided by a U.S vendor. All the NP swab specimens were confirmed as positive or negative by an EUA RT-PCR as a comparator method prior to the study.

**Test Result:**

Candidate method		RT-PCR method		
		Positive	Negative	Total
Flowflex Test Results	Positive	7	0	7
	Negative	0	30	30
	Total	7	30	37

Sensitivity: 100% (95% CI: 59.0%-100%)

Specificity: 100% (95% CI: 88.4%-100%)

**2.3.5 Conclusions:**

The sensitivity, specificity, and accuracy are meeting MHRA acceptable requirement, which has sensitivity greater than 80% and specificity greater than 95%.

**2.4 Cross Reactivity (Analytical Specificity)**



To demonstrate the related pathogens and microorganisms that are reasonably likely to be present in the nasal cavity do not interfere with test performance of Flowflex SARS-Cov-2 Antigen Test.

**Material:**

- SARS-CoV-2 Antigen Rapid Test, Lot#202009001
- Extraction Buffer, Lot#102820
- Pooled human negative matrix

**Procedure:** Cross-Reactivity Wet Testing

Samples were prepared by spiking each stock microorganism into the pooled human negative matrix. Each microorganism was tested in triplicate with Flowflex SARS-CoV-2 Antigen Rapid Test.

**Test Results:**

No cross-reactivity was observed with the following bacteria and viruses when tested at the concentration presented in the table below.

Potential Cross -Reactant		Test Concentration	Cross-Reactivity (in the absence of SARS-CoV-2 virus)
Virus	Adenovirus	1.14 x 10 <sup>6</sup> TCID <sub>50</sub> /mL	No 3/3 negative
	Enterovirus	9.50 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 negative
	Human coronavirus 229E	1.04 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 negative
	Human coronavirus OC43	2.63 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 negative
	Human coronavirus NL63	1.0 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 negative
	Human Metapneumovirus	1.25 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 negative
	MERS-coronavirus	7.90 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 negative
	Influenza A	1.04 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 negative
	Influenza B	1.04 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 negative
	Parainfluenza virus 1	1.25 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 negative
	Parainfluenza virus 2	3.78 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 negative
	Parainfluenza virus 3	1.0 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 negative
	Parainfluenza virus 4	2.88 x 10 <sup>6</sup> TCID <sub>50</sub> /mL	No 3/3 negative
	Respiratory syncytial virus	3.15 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 negative
Rhinovirus	3.15 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 negative	
Bacteria	Bordetella pertussis	2.83 x 10 <sup>9</sup> CFU/mL	No 3/3 negative
	Chlamydia trachomatis	3.13 x 10 <sup>8</sup> CFU/mL	No 3/3 negative
	Haemophilus influenzae	1.36 x 10 <sup>8</sup> CFU/mL	No 3/3 negative
	Legionella pneumophila	4.08 x 10 <sup>9</sup> CFU/mL	No 3/3 negative
	Mycobacterium tuberculosis	1.72 x 10 <sup>7</sup> CFU/mL	No 3/3 negative
	Mycoplasma pneumoniae	7.90 x 10 <sup>7</sup> CFU/mL	No 3/3 negative
	Staphylococcus aureus	1.38 x 10 <sup>7</sup> CFU/mL	No 3/3 negative

	Staphylococcus epidermidis	2.32 x 10 <sup>9</sup> CFU/mL	No 3/3 negative
	Streptococcus pneumoniae	1.04 x 10 <sup>8</sup> CFU/mL	No 3/3 negative
	Streptococcus pyogenes	4.10 x 10 <sup>6</sup> CFU/mL	No 3/3 negative
	Pneumocystis jirovecii-S. cerevisiae	8.63 x 10 <sup>7</sup> CFU/mL	No 3/3 negative
	Pseudomonas aeruginosa	1.87 x 10 <sup>8</sup> CFU/mL	No 3/3 negative
Yeast	Candida albicans	1.57 x 10 <sup>8</sup> CFU/mL	No 3/3 negative

Flowflex SARS-CoV-2 Antigen Rapid Test does not differentiate between SARS-CoV and SARS-CoV-2.

## 2.5 Microbial Interference Studies

To demonstrate that false negatives will not occur with Flowflex SARS-Cov-2 Antigen Test when SARS-CoV-2 is present in a specimen with other microorganisms.

### Material:

- SARS-CoV-2 Antigen Rapid Test, Lot# 202009001
- Heat inactivated SARS-CoV-2 virus: Isolate USA-WA1/2020, Cat# 0810587CFHI, Lot#324615
- Extraction Buffer, Lot#102820
- Pooled human negative matrix

### Procedure:

The samples were prepared by spiking each microorganism and the heat inactivated SARS-CoV-2 virus into the pooled human negative matrix. Each microorganism in the presence of low concentration of the heat inactivated SARS-CoV-2 virus was tested in triplicate with Flowflex SARS-CoV-2 Antigen Rapid Test.

### Test Results:

No interference was observed in the presence of heat inactivated SARS-CoV-2 virus with the following bacteria and viruses when tested at the concentration presented in the table below.

	Potential Cross -Reactant	Test Concentration	Interference (in the presence of SARS-CoV-2 virus)
Virus	Adenovirus	1.14 x 10 <sup>6</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	Enterovirus	9.50 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	Human coronavirus 229E	1.04 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	Human coronavirus OC43	2.63 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	Human coronavirus NL63	1.0 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	Human Metapneumovirus	1.25 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	MERS-coronavirus	7.90 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	Influenza A	1.04 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	Influenza B	1.04 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	Parainfluenza virus 1	1.25 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	Parainfluenza virus 2	3.78 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	Parainfluenza virus 3	1.0 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	Parainfluenza virus 4	2.88 x 10 <sup>6</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	Respiratory syncytial virus	3.15 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 positive
	Rhinovirus	3.15 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No 3/3 positive
Bacteria	Bordetella pertussis	2.83 x 10 <sup>9</sup> CFU/mL	No 3/3 positive
	Chlamydia trachomatis	3.13 x 10 <sup>8</sup> CFU/mL	No 3/3 positive
	Haemophilus influenzae	1.36 x 10 <sup>8</sup> CFU/mL	No 3/3 positive
	Legionella pneumophila	4.08 x 10 <sup>9</sup> CFU/mL	No 3/3 positive
	Mycobacterium tuberculosis	1.72 x 10 <sup>7</sup> CFU/mL	No 3/3 positive
	Mycoplasma pneumoniae	7.90 x 10 <sup>7</sup> CFU/mL	No 3/3 positive
	Staphylococcus aureus	1.38 x 10 <sup>7</sup> CFU/mL	No 3/3 positive

	Staphylococcus epidermidis	2.32 x 10 <sup>9</sup> CFU/mL	No 3/3 positive
	Streptococcus pneumoniae	1.04 x 10 <sup>8</sup> CFU/mL	No 3/3 positive
	Streptococcus pyogenes	4.10 x 10 <sup>6</sup> CFU/mL	No 3/3 positive
	Pneumocystis jirovecii-S. cerevisiae	8.63 x 10 <sup>7</sup> CFU/mL	No 3/3 positive
	Pseudomonas aeruginosa	1.87 x 10 <sup>8</sup> CFU/mL	No 3/3 positive
Yeast	Candida albicans	1.57 x 10 <sup>8</sup> CFU/mL	No 3/3 positive

**Conclusion:**

Based on the data generated by this study, the microorganisms tested do not cross-react or interfere with Flowflex SARS-CoV-2 Antigen Rapid Test.

**2.6 Endogenous Interfering Substances**

To determine if the substances that naturally present in respiratory specimens or that may be artificially introduced into the nasal cavity interfere with Flowflex SARS-CoV-2 Antigen Rapid Test.

**Material:**

- SARS-CoV-2 Antigen Rapid Test, Lot# 202009001
- Heat inactivated SARS-CoV-2 virus: Isolate USA-WA1/2020, Cat# 0810587CFHI, Lot#324615
- Extraction Buffer, Lot# 102820
- Pooled human negative matrix

**Procedure 1:** Test the endogenous substances in the absence of heat inactivated SARS-CoV-2 virus.

The samples were prepared by spiking each substance into the human negative matrix to the test concentration listed in the table below. Each sample was tested in triplicate with Flowflex SARS-CoV-2 Antigen Rapid Test according to the package insert.

**Test Results:**

No cross-reactivity was observed with the endogenous interfering substances when tested at the concentration presented in the table below.

**Procedure 2:** Test the endogenous substances in the presence of heat inactivated SARS-CoV-2 virus.

The samples were prepared by spiking each substance and heat inactivated SARS-CoV-2 virus into the human negative matrix to the test concentration in the presence of low concentration of heat inactivated SARS-CoV-2 virus. Each sample was tested in triplicate according to the package insert.

**Test Results:**

No interference was observed.

**Endogenous Interference Substances Study Results**

Interfering Substance	Active Ingredient	Concentration	Test Results (in the absence of SARS-CoV-2 virus)	Test Results (in the presence of SARS-CoV-2 virus)
Endogenous	Biotin	2.4 mg/mL	3/3 negative	3/3 positive
	Mucin	0.5% w/v	3/3 negative	3/3 positive
	Whole Blood	4% v/v	3/3 negative	3/3 positive
Afrin Original Nasal Spray	Oxymetazoline	15% v/v	3/3 negative	3/3 positive
ALKALOL Allergy Relief Nasal Spray	Homeopathic	1:10 Dilution	3/3 negative	3/3 positive
Chloraseptic Max Sore Throat Lozenges	Menthol, Benzocaine	1.5 mg/mL	3/3 negative	3/3 positive
CVS Health Fluticasone Propionate Nasal Spray	Fluticasone propionate	5% v/v	3/3 negative	3/3 positive
Equate Fast-Acting Nasal Spray	Phenylephrine	15% v/v	3/3 negative	3/3 positive
Equate Sore Throat Phenol Oral Anesthetic Spray	Phenol	15% v/v	3/3 negative	3/3 positive
Original Extra Strong Menthol Cough Lozenges	Menthol	1.5 mg/mL	3/3 negative	3/3 positive
NasalCrom Nasal Spray	Cromolyn	15% v/v	3/3 negative	3/3 positive
NeilMed NasoGel for Dry Noses	Sodium Hyaluronate	5% v/v	3/3 negative	3/3 positive
Throat Lozenge	Dyclonine Hydrochloride	1.5mg/mL	3/3 negative	3/3 positive
Zicam Cold Remedy	Galphimia glauca, Luffa operculata, Sabadilla	5% v/v	3/3 negative	3/3 positive
Antibiotic	Mupirocin	10 mg/mL	3/3 negative	3/3 positive
Tamiflu	Oseltamivir Phosphate	5 mg/mL	3/3 negative	3/3 positive
Antibiotic	Tobramycin	4 µg/mL	3/3 negative	3/3 positive

**Conclusion:**

Based on the data generated by this study, the endogenous interfering substances tested do not cross-react or interfere with Flowflex SARS-CoV-2 Antigen Rapid Test.

## 2.7 Hook effect

To evaluate if the false negative result can be observed when test very high levels of heat inactivated SARS-CoV-2 virus with Flowflex SARS-Cov-2 Antigen Rapid Test.

### Material:

- SARS-CoV-2 Antigen Rapid Test, Lot# 202009001
- Heat inactivated SARS-CoV-2 virus: Isolate USA-WA1/2020, Cat# 0810587CFHI, Lot#324615
- Extraction Buffer, Lot#102820
- Pooled human negative clinical matrix

### Procedure:

The nasal swabs from healthy donors were collected and eluted with PBS buffer. The swab eluates were combined and mixed thoroughly to create a negative clinical matrix pool. The heat-inactivated SARS-CoV-2 virus was diluted in the negative clinical matrix pool to generate a positive sample.

For each test, 50 µL of the positive sample was added to a nasal swab. The spiked swab was processed in the extraction buffer tube and tested on the Flowflex SARS CoV-2 Antigen Rapid Test according to the package insert. The testing concentration for the heat-inactivated SARS-CoV-2 virus was  $1.43 \times 10^5$  TCID<sub>50</sub>/mL.

### Conclusion:

No high dose hook effect was observed when tested with up to a concentration of  $1.43 \times 10^5$  TCID<sub>50</sub>/mL of heat inactivated SARS-CoV-2 virus with Flowflex SARS-CoV-2 Antigen Rapid Test.

## 2.8 Read Time Flex

To demonstrate that the test result is stable when read within the recommended time window.

### Material:

SARS-CoV-2 Antigen Rapid Test, Lot# COV0110005

Buffer, Lot#: TDE20110009

SARS-CoV-2 Antigen Negative Sample Lot#: 20201104

SARS-CoV-2 Antigen Low Positive Control Lot#: COVAG200930L

SARS-CoV-2 Antigen Middle Positive Control Lot#: COVAG200930M

ACON Rapid Flow Test Color Card, Lot#20200112

**Procedure:**

SARS-CoV-2 Antigen negative, high, middle and low positive sample are tested with SARS-CoV-2 Antigen Rapid Test according to package insert. Each test was performed in triplicate. The test results were recorded at 5, 10, 15, 20 and 30 mins.

**Test results:**

SARS-CoV-2 Samples	5 min	10 min	15 min	20 min	30 min
Neg	- / 3 replicates	- / 3 replicates	- / 3 replicates	- / 3 replicates	- / 3 replicates
Low Pos	- / 3 replicates	+ / 3 replicates	+ / 3 replicates	+ / 3 replicates	+ / 3 replicates
Mid Pos	+ / 3 replicates	+ / 3 replicates	+ / 3 replicates	+ / 3 replicates	+ / 3 replicates
High Pos	+ / 3 replicates	+ / 3 replicates	+ / 3 replicates	+ / 3 replicates	+ / 3 replicates

**Conclusion:**

The results are stable when read between 10 minutes to 30 minutes.

**2.9 Stability Study****Material:**

- SARS-CoV-2 Antigen Rapid Test, Lot#1:202009101, Lot#2:202009001, Lot#3:202009201
- Extraction Buffer, Lot1#:202008001, Lot2#:202008002, Lot3#:202008003
- SARS-CoV-2 Antigen Negative Sample Lot#: COVAG200904N
- SARS-CoV-2 Antigen Low Positive Sample P3 Lot#: COVAG200904P3
- SARS-CoV-2 Antigen Middle Positive Sample P2 Lot#: COVAG200904P2
- SARS-CoV-2 Antigen High Positive Sample P1 Lot#: COVAG200904P1
- SARS-CoV-2 Antigen positive control swab, Lot#1: 202009003P-1, Lot#2: 202009003P-2, Lot#3: 202009003P-3
- SARS-CoV-2 Antigen negative control swab, Lot#1: 202009003N-1, Lot#2: 202009003N-2, Lot#3: 202009003N-3

**2.9.1 Accelerated stability**

Estimate the shelf life for SARS-CoV-2 Antigen Rapid Test, Extraction Buffer and Control Swabs basing on the accelerate stability study.

**Procedure:**

Accelerated stability study for three lots (including tests in individual pouches, control swabs in individual pouches, extraction buffer in tube) will be stored at 55°C/65°C to estimate product stability. Tests will be assayed according to package insert at designated time points. For each device lot, run 3 replicates per sample at each time points. Read the results according to package insert.



**Test results:**

Result of SARS-CoV-2 Antigen Rapid Test

**55°C**

SARS-CoV-2 Samples	0 day	7 days	14 days
Neg	- / 3 tests x 3 lots	- / 3 tests x 3 lots	- / 3 tests x 3 lots
Low Pos	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots
Mid Pos	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots
High Pos	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots

**65°C**

SARS-CoV-2 Samples	0 day	7 days	14 days
Neg	- / 3 tests x 3 lots	- / 3 tests x 3 lots	- / 3 tests x 3 lots
Low Pos	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots
Mid Pos	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots
High Pos	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots

Result of SARS-CoV-2 Antigen Control swab:

**55°C**

Samples	0 day	7 days	14 days
Positive Control Swab	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots
Negative Control Swab	- / 3 tests x 3 lots	- / 3 tests x 3 lots	- / 3 tests x 3 lots

**65°C**

Samples	0 day	7 days	14 days
Positive Control Swab	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots
Negative Control Swab	- / 3 tests x 3 lots	- / 3 tests x 3 lots	- / 3 tests x 3 lots

**Conclusion:**

SARS-CoV-2 Antigen Rapid Test, extraction buffer and SARS-CoV-2 Antigen Control Swabs are stable at 65°C for 14 days, so the shelf life can be estimated at least 24 months.

### 2.9.2 Real time stability

Estimate the shelf life for SARS-CoV-2 Antigen Rapid Test, Extraction Buffer and Control Swabs basing on the real time stability study.

#### Procedure:

Real time stability study for three lots (including tests in individual pouches, control swabs in individual pouches, extraction buffer in tube) will be stored at 2-8°C/30°C to estimate product stability. Tests will be assayed according to package insert at designated time points every 3 months until the timepoints that performance does not meet the acceptance criteria. For each device lot, negative and different levels of positive samples will be tested, run 3 replicates per sample at each time points. Read the results according to package insert.

Acceptance criteria:

Negative sample will generate negative result

Low positive, medium positive and high positive sample will generate positive results

#### Test results:

##### Result of SARS-CoV-2 Antigen Rapid Test:

#### 2-8°C

SARS-CoV-2 Samples	Neg	Low Pos	Mid Pos	High Pos
0 day	- / 3 tests x 3 lots	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots
3 months				
6 months				
9 months				
12 months				

#### 30°C

SARS-CoV-2 Samples	Neg	Low Pos	Mid Pos	High Pos
0 day	- / 3 tests x 3 lots	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots	+ / 3 tests x 3 lots
3 months				
6 months				
9 months				
12 months				

Result of SARS-CoV-2 Antigen Control swab:

**2-8°C**

SARS-CoV-2 Samples	Neg control swab	Pos control swab
0 day	- / 3 tests x 3 lots	+ / 3 tests x 3 lots
3 months		
6 months		
9 months		
12 months		

**30°C**

SARS-CoV-2 Samples	Neg control swab	Pos control swab
0 day	- / 3 tests x 3 lots	+ / 3 tests x 3 lots
3 months		
6 months		
9 months		
12 months		

**Conclusion:**

The real time stability of SARS-CoV-2 Antigen Rapid Test, extraction buffer and SARS-CoV-2 Antigen Control Swab are still in process. It is scheduled to finish in December 2022.

**2.10 Mimicking Shipping Study**

To evaluate the performance of Flowflex SARS-CoV-2 Antigen Rapid Test by mimicking shipping conditions.

**Materials:**

	SARS-CoV-2 Antigen Rapid Test, Lot1	SARS-CoV-2 Antigen Rapid Test, Lot2	SARS-CoV-2 Antigen Rapid Test, Lot3
Test lot number	Lot 202009101	Lot 202009001	Lot 202009201
Negative control swab	Lot 202009003N-1	Lot 202009003N-2	Lot 202009003N-3
Positive control swab	Lot 202009003P-1	Lot 202009003P-2	Lot 202009003P-3

Heat-inactivated SARS-CoV-2 virus: ZeptoMetrix Corporation, Lot#324615

Dry ovens

Refrigerator, -20°C

**Method:**

**1) Study at 3XFT/25°C:**

SARS-CoV-2 Antigen Rapid Tests were stored at -20°C for 24 hours and then stored at RT for 24 hours. 3 freeze/thaw cycles were repeated to mimic harsh shipping conditions. At the last thaw, the products were stored at 65°C for a certain period. Performed the tests with control swabs, negative and positive samples in 5 replicates at designated timepoints as below:

Temperature	Day 0	Day 7	Day 14
65°C	X	X	X

The nasal swabs from healthy volunteers were collected and eluted with PBS buffer. The swab eluates were combined and mixed thoroughly to create a negative clinical matrix pool. The heat-inactivated SARS CoV-2 virus was spiked in the negative clinical matrix pool to generate a positive sample.

50 ul of negative clinical matrix pool and spiked positive sample were applied to each swab, respectively. The swab was inserted to the extraction buffer tube, processed and tested with SARS CoV-2 Antigen Rapid Test following package insert at different time point and different mimic shipping condition. Each sample was tested in 5 replicates.

**2) Shipping under condition of 55°C for two days.**

Accelerated stability study at 55°C was performed for 35 days in a separated study report, which supports that product still maintain good stability after 55°C/2 days shipping condition.

**Accepted Criteria:**

Negative control swab and negative sample should generate negative results.

Positive control swab and positive sample should generate positive results.

**Results:**

**Test Result of 3XFT/25°C:**

1) Accelerated stability study results with lot 1:

**Results with quality control swabs:**

65°C stability with Lot 1	Day 0	Day 7	Day 14
Negative control swab	- (5/5)	- (5/5)	- (5/5)
Positive control swab	+ (5/5)	+ (5/5)	+ (5/5)

The results at 15min were the same as at 30min

**Results with contrived samples:**

65°C stability with Lot 1	Day 0	Day 7	Day 14
Negative specimen	- (5/5)	- (5/5)	- (5/5)
Low positive specimen	+ (5/5)	+ (5/5)	+ (5/5)

The results at 15min were the same as at 30min

2) Accelerated stability study results with lot 2:

**Results with quality control swabs:**

65°C stability with Lot 2	Day 0	Day 7	Day 14
Negative control swab	- (5/5)	- (5/5)	- (5/5)
Positive control swab	+ (5/5)	+ (5/5)	+ (5/5)

The results at 15min were the same as at 30min

**Results with contrived samples:**

65°C stability with Lot 2	Day 0	Day 7	Day 14
Negative specimen	- (5/5)	- (5/5)	- (5/5)
Low positive specimen	+ (5/5)	+ (5/5)	+ (5/5)

The results at 15min were the same as at 30min

3) Accelerated stability study results with lot 3:

**Results with quality control swabs:**

65°C stability with Lot 3	Day 0	Day 7	Day 14
Negative control swab	- (5/5)	- (5/5)	- (5/5)
Positive control swab	+ (5/5)	+ (5/5)	+ (5/5)

The results at 15min were the same as at 30min

**Results with contrived samples:**

65°C stability with Lot 3	Day 0	Day 7	Day 14
Negative specimen	- (5/5)	- (5/5)	- (5/5)
Low positive specimen	+ (5/5)	+ (5/5)	+ (5/5)

The results at 15min were the same as at 30min

**The Result of 55°C for two days:**

Product performance met the acceptable criteria under the shipping condition of 55°C for two days (detailed results are available in **2.9.1** Accelerated stability study).

**Conclusion:**

The study results of mimicking shipping condition support that the shelf life of SARS-CoV-2 Antigen Rapid Test is over two years under mimic harsh shipping conditions.

**2.11 Matrix equivalence study**

**Materials:**

- SARS-CoV-2 Antigen Rapid Test, Lot#3:202009201
- SARS-CoV-2 viral culture
- Negative nasal matrix sample pool
- Negative nasopharyngeal matrix sample pool

**Procedure:**

1) Diluted the high concentration SARS-CoV-2 virus culture with the negative nasal matrix sample pool to  $2.56 \times 10^3$  TCID50/mL. And then diluted the  $2.56 \times 10^3$  TCID50/mL sample with negative nasal matrix sample pool to one low positive (3 x LOD) and three moderately positive (5 x LOD, 6 x LOD and 7 x LOD).

2) Diluted the high concentration SARS-CoV-2 virus culture with the negative nasopharyngeal matrix sample pool to  $2.56 \times 10^3$  TCID50/mL. And then diluted the  $2.56 \times 10^3$  TCID50/mL sample with negative nasopharyngeal matrix sample pool to one low positive (3 x LOD) and three moderately positive (5 x LOD, 6 x LOD and 7 x LOD).

3) Blinding and randomization of the four positive nasal specimens, four positive nasopharyngeal specimens, one negative nasal specimen and one negative nasopharyngeal specimen were tested in duplicate, and compare the results between the matrices.

**Test Results:**

Sample	Nasal Specimen		Nasopharyngeal Specimen	
Negative	-	-	-	-
Low positive (3 x LOD)	+	+	+	+
Moderately positive (5 x LOD)	+	+	+	+
Moderately positive (6 x LOD)	+	+	+	+
Moderately positive (7 x LOD)	+	+	+	+

**Conclusion**

According to the test result above, there is no difference between nasal and nasopharyngeal swab specimens for SARS-CoV-2 Antigen Rapid Test.